The Coming Intersection of Nanotechnology and Synthetic Biology With Insurance

April 24, 2009

Foley Partner and chair of the Health Care Industry Team Mark Waxman and Partner Ethan Lenz authored an article titled, “The Coming Intersection of Nanotechnology and Synthetic Biology With Insurance,” in the April 24, 2009 issue of BNA’s Life Sciences Law & Industry Report.

Reproduced with permission from BNA’s Life Sciences Law & Industry Report, by The Bureau of National Affairs, Inc. http://www.bna.com.

Authors

Ethan D. Lenz

Sectors

Health Care & Life Sciences

Practice Areas

Health Care

Author(s)

Ethan D. Lenz

elenz@foley.com

Madison 414.297.5835

Related Insights

View All Posts

June 3, 2025 Foley Corporate Governance Update

Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders

On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.

September 25, 2025 Events

Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners 

June 3, 2025 Health Care Law Today

GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.